An Early Phase 1 interventional study of Ranibizumab Injection [Lucentis] and Aflibercept Injection [Eylea] in Diabetic Macular Edema, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Sohag University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.
Among the 22 studies in Macular Edema with a site in Egypt, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 1, and was the 17th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:
Khadija Ahmed Mhrose Glal · Sites in Egypt
Ages 19–69
The General Authority for Teaching Hospitals and Institutes · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 35 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 2 · Phase 4 6
First in 2010; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 17 interventional studies, 52 across the 5 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 3 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Macular Edema with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07917338Khadija Ahmed Mhrose GlalOral N-Acetylcysteine on Diabetic Macular Edema | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Macular Edema with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR . Retinal oedema is responsible for retinal micro-structural alterations, retinal atrophy of photoreceptors and ganglion cell disorders . In addition, it might be considered consensual that the best improvements in VA could be accomplished when retinal oedema is managed. In the context of a chronic and progressive disease, DME has to be faced as a state to control as effectively and rapidly as possible . Vascular endothelial growth factor (VEGF) is a protein that promotes the growth of new blood vessels. It also makes the blood vessels more leaky. Anti- VEGF medicines stop the growth of these new blood vessels. This prevents damage to the retinal light receptors and loss of central vision. The DME treatment has been shifted from the laser photocoagulation to anti-VEGF therapy . The advantages of anti-VEGF therapy in decreasing DME and improving patient's vision have been reported in many studies . Ranibizumab, in addition to aflibercept, have been reported as the first line therapies among the other anti-VEGF . There are several data demonstrating the efficiency of ranibizumab in treatment of patients with DME . On the other hand, there are studies that revealed poor response of some patients to anti-VEGF therapies even after 3 or more injections Non-modifiable risk factors for diabetic retinopathy are gender and DM duration.
Modifiable risk factors contributing to the development of diabetic retinopathy are elevated blood sugar levels, blood pressure, and dyslipidemia which is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetic . Hard exudates are thought to be induced by the leakage of lipids from dysfunctional retinal capillaries . Therefore, theses were formulated that higher levels of total cholesterol, LDL-C and triglycerides could be considered biomarkers of the development of hard exudates in DM patients . Aim of the work
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
change in the best corrected visual acuity in meters
measure of the ability of the eye to distinguish shapes and the details of objects at a given distance with the help of corrective lenses
Time frame: 2 months
change in the retina and macula measurements by Optical coherence tomography (OCT)
assess the state of the retina and macula by measuring : * Average Thickness in (μm)
Time frame: 2 months
change in the retina and macula measurements by Optical coherence tomography (OCT)
assess the state of the retina and macula by measuring : * Center thickness in (μm)
Time frame: 2 months
change in the retina and macula measurements by Optical coherence tomography (OCT)
assess the state of the retina and macula by measuring : * Total volume in (mm3)
Time frame: 2 months
Started Dec 2023 (actual). Primary completion is estimated for Jun 2024, 6 months after the start.
Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.